

An abstract background featuring a blue and white DNA double helix on the right side. In the center, a hand in a white surgical glove holds a surgical scalpel. The background is a mix of light blue and white with faint molecular structures.

Pankreas Duktal Adenokarsinomu (PDAK)

- Kanserle bağılı ölümlerde her iki kanser 4. sırada
- Sistemik onkolojik tedavilerde daha iyi
- %10-18 hasta cerrahi yapılabilir
- Erken nüks: % 20-40
- Cerrahi en küratif tedavi

The 5-year survival rate for pancreatic cancer increased to

Together
We're Changing
the Story

12%

American Cancer Society, Cancer Facts and Figures, 1999-2003

MIPIC

Üstünlükleri

- Kan kaybı anlamlı az
- Hastanede kalış süresi az
- Postop ağrı az
- Hızlı iyileşme

Zorlukları

- Öğrenme eğrisi uzun
- Cerrahi süresi uzun
- POPF (öğrenme eğrisinde yüksek)
- Yüksek Maliyet

www.cerrahiankolajoligida.org

MiPC-PDAK


Laparoskopik / Robotik

- Pankreatikoduodenektomi (PD)
- Distal Pankreatektomi (DP)
- Total Pankreatektomi (TP)



MIPD

- Öğrenme eğrisi uzun, zor, karışık
- LPD ve RPD < %10'nun (ABD)
- Robot platformu
- Yapılandırılmış eğitim program ile
- %6.4- %9.4 (2014-2020)



The presentation slide titled "Standardization of Learning Curves in Pancreatic Surgery" outlines a structured approach to learning curves. It includes a table of 66 studies, a bar chart showing the number of procedures for the first phase of learning curves across different countries, and a list of parameters used to define learning curves. The table lists studies by author, year, and number of cases. The bar chart shows the number of procedures for the first phase of learning curves for the United States, Japan, Korea, and the United Kingdom. The parameters used to define learning curves include Phase 1 Competency, Phase 2 Proficiency, Phase 3 Mastery, Operative time, Blood loss, Conversion rate, Length of stay, and Complication rate.

Author	Year	Number of cases
Cheng	2012	100
Cheng	2013	100
Cheng	2014	100
Cheng	2015	100
Cheng	2016	100
Cheng	2017	100
Cheng	2018	100
Cheng	2019	100
Cheng	2020	100
Cheng	2021	100
Cheng	2022	100
Cheng	2023	100
Cheng	2024	100
Cheng	2025	100
Cheng	2026	100
Cheng	2027	100
Cheng	2028	100
Cheng	2029	100
Cheng	2030	100
Cheng	2031	100
Cheng	2032	100
Cheng	2033	100
Cheng	2034	100
Cheng	2035	100
Cheng	2036	100
Cheng	2037	100
Cheng	2038	100
Cheng	2039	100
Cheng	2040	100
Cheng	2041	100
Cheng	2042	100
Cheng	2043	100
Cheng	2044	100
Cheng	2045	100
Cheng	2046	100
Cheng	2047	100
Cheng	2048	100
Cheng	2049	100
Cheng	2050	100
Cheng	2051	100
Cheng	2052	100
Cheng	2053	100
Cheng	2054	100
Cheng	2055	100
Cheng	2056	100
Cheng	2057	100
Cheng	2058	100
Cheng	2059	100
Cheng	2060	100
Cheng	2061	100
Cheng	2062	100
Cheng	2063	100
Cheng	2064	100
Cheng	2065	100
Cheng	2066	100
Cheng	2067	100
Cheng	2068	100
Cheng	2069	100
Cheng	2070	100
Cheng	2071	100
Cheng	2072	100
Cheng	2073	100
Cheng	2074	100
Cheng	2075	100
Cheng	2076	100
Cheng	2077	100
Cheng	2078	100
Cheng	2079	100
Cheng	2080	100
Cheng	2081	100
Cheng	2082	100
Cheng	2083	100
Cheng	2084	100
Cheng	2085	100
Cheng	2086	100
Cheng	2087	100
Cheng	2088	100
Cheng	2089	100
Cheng	2090	100
Cheng	2091	100
Cheng	2092	100
Cheng	2093	100
Cheng	2094	100
Cheng	2095	100
Cheng	2096	100
Cheng	2097	100
Cheng	2098	100
Cheng	2099	100
Cheng	2100	100

7th CONGRESS
OF
PANCREATOLOGY
AND
BILIARY DISEASES
2024

Outcomes After Minimally-Invasive Versus Open Pancreatoduodenectomy

A Pan-European Propensity Score Matched Study

Sören Klingmeyer, MD¹, Jory van Hilst, MD, MSc², Ulrich F. Wellner, MD, |||||
 Oliver R. Busch, MD³, Andrea Ceratti, MD⁴, Markus D. Hohn, MD⁵, Safi Daldem, |||||
 Sebastian Freier, MD, PhD⁶, ~~Matthias Kretschmer~~, MD ||| Ugo Khawam, MD, PhD⁷, |||||
 Dham J. Lige, MD, PhD⁸, Jorge Lombardi, MD, PhD⁹, Mihai Leiva, MD, PhD⁸, Alberte Maymou, MD¹⁰,
 Işık G. Melamed, MD, PhD¹¹, Eduardo Rosau, MD¹², Oliver Saint-Marc, MD¹³,
 Franky Vantermeulen, MD¹⁴, Uwe A. Wied, MD ||||| Roy Berman, MD, PhD¹⁵,
 Bas Geert Koeckamp, MD, PhD¹⁶, Mohammed Abu Hilal, MD, PhD, FRCS, FACS¹⁷,
 David Fakis, MD, PhD¹⁸, Ignace Fievez, MD, PhD ||| Tobias Krenn, MD, PhD¹⁹, |||||
 Ugo Boggi, MD²⁰ and Marc G. Besselink, MD, MSc, PhD²¹ for the
 European consortium on Minimally Invasive Pancreatic Surgery (E-MIPS)

- 7 Ülke, 14 Merkez
- 730 MIPD
- Yilda > 10 olgu
- Mortalite/ Morbidite açısından fark yok

Conclusions: In the early experience of 14 European centers performing ≥ 10 MIPDs annually, no differences were found in major morbidity, mortality, and hospital stay between MIPD and OPD. The high rates of POPF and conversion, and the lack of superior outcomes (ie, hospital stay, morbidity) could indicate that more experience and higher annual MIPD volumes are needed.

www.europanclogipg2024.org


2020;27(12):356-363.

JAMA Surgery | Original Investigation

Effects of Pancreatic Fistula After Minimally Invasive and Open Pancreatoduodenectomy

Caro L. Bruna, MD; Anouk M. L. H. Emmen, MD; Kongyuan Wei, MD, PhD; Robert P. Sutcliffe, MD; Baiyong Shen, MD, PhD; Giuseppe K. Fusai, MD, PhD; Yi-Ming Shyr, MD, PhD; Igor Khatkov, MD, PhD; Steve White, MD, PhD; Leia R. Jones, BSc; Alberto Manzoni, MD, PhD; **Mustafa Kerem**, MD, PhD; Bas Groot Koerkamp, MD, PhD; Clarissa Ferrari, PhD; Olivier Saint-Marc, MD, PhD; I. Quintus Molenaar, MD, PhD; Claudio Bnà, MD; Safi Dokmak, MD, PhD; Ugo Boggi, MD, PhD; Rong Liu, MD, PhD; Jin-Young Jang, MD, PhD; Marc G. Besselink, MD, PhD; Mohammad Abu Hilal, MD, PhD; for the International Consortium on Minimally Invasive Pancreatic Surgery (I-MIPS)

JAMA Surg. doi:10.1001/jamasurg.2024.5412
Published online December 4, 2024.



	MIPD POPF (B/C), N=336/558	Açık PD POPF (B/C) N=336/572	P
Sekonder komplikasyonlar	129 (% 55)	95 (% 36)	<0.001
Postpankreatektomi kanama	71 (%21)	22 (% 8)	<0.001
Hastanede kalış (gün)	27 (18-38)	22 (15-30)	<0.001
Re-operasyon	67 (%21)	21 (%7)	<0.001

JAMA Surg. doi:10.1001/jamasurg.2024.5412
Published online December 4, 2024.

www.cerrahionkoloji2024.org

	RPD POPF (B/C), N=225	LPD POPF (B/C) N=111	P
DGE B/C	51 (%22.8)	14 (% 12.6)	<0.001
Re-operasyon	37 (17.5)	31 (27.9)	<0.001

CONCLUSIONS AND RELEVANCE This study found that for patients after MIPD, the presence of POPF is more frequently associated with other clinically relevant complications compared with OPD. This underscores the importance of perioperative mitigation strategies for POPF and the resulting PPH in high-risk patients.

JAMA Surg. doi:10.1001/jamasurg.2024.5412
Published online December 4, 2024.

www.cerrahionkoloji2024.org

LPD vs OPD		
Randomize Kontrollü Çalışmalar		
Çalışma Adı	Hasta Sayısı	Notlar
LEOPARD-2	100	Laparoskopik ve açık cerrahiler eşit onkolojik sonuçlar, Ancak öğrenme eğrisi dikkat edilmelidir.
PORTAL	150	Robotik cerrahinin güvenliği ve etkinliği değerlendirildi, sonuçlar uzun vadede olumlu.
PLOT	80	Laparoskopik yaklaşımda daha az kan kaybı ve kısa iyileşme zamanı. Onkolojik sonuçlar açıkça benzer

J Robotik Surg. 2024;18-85

www.cerrahionkoloji2024.org

RPD vs OPD								
Table 2. Studies comparing oncologic outcomes for RPD in reference to OPD								
Study	Year	Study type	PDAC patients	RO	LN	OS (months)	Overall POPF*	CR-POPF*
Chalikonda et al.	2012	Single-institution (PM)	14 LRPD vs 14 OPD	(100% vs 87%, p=0.002)	(13.2 vs 11.76, p=0.25)	—	14.38% of LRPD patients	14.38% of LRPD patients
Zureikat et al.	2016	Multi-institution	70 RPD vs 452 OPD	(50% vs 69%, p=0.002)	(27.5 vs 19, p<0.001)	—	(13.74% vs 9.08%, p=0.04)	(13.74% vs 9.08%, p=0.04)
Cai et al.	2020	Single-institution	226 RPD vs 231 OPD	—	—	—	(20.4% vs 23.5%, p=0.283)	(6.7% vs 15.8%, p<0.001)
Balmain-George et al.	2020	Single-institution (PM)	38 RPD vs 38 OPD	(57.9% vs 55.3%, p=0.817)	(21.5 vs 13.5, p=0.0036)	(30.4 vs 23.0, p=0.1105)	(10.5% vs 13.2%, p=0.727)	—
Nassour et al.	2020	NCDB	626	(77% vs 78%, p=0.052)	(22 vs 17, p<0.001)	(22.0 vs 21.8, p=0.755)	—	—
Vining et al.	2020	ACS-NSQIP	271 RPD vs 6,885 OPD	—	—	—	(14.7% vs 18.1%, p=0.0534)	(11.9% vs 15.6%, p=0.026)

*: Among PDAC and non-PDAC patients, -: data unavailable

J Robotik Surg. 2024;18-85

www.cerrahionkoloji2024.org

RPD vs LPD							
Study	Year	Study type	PDAC patients	R0	LNR	OS (months)	Overall POPF* CR-POPF*
Torphy et al.	2019	NCDB	549 RPD vs 3,205 LPD	(83.4% vs 82.0%, $p=0.755$)	(51.9% vs 47.5%, $p=0.176$ *)	–	–
Vining et al.	2020	ACS-NSQIP	271 RPD vs 216 LPD	–	–	–	(14.7% vs 17.5%, $p=0.2638$) (11.9% vs 14.0%, $p=0.3550$)
Chopra et al.	2021	Single-institution	146	–	–	++	–

*: among PDAC and non-PDAC patients. -: data unavailable

MIDP							
• Daha fazla tecrübe ve kanıt var • Vasküler rezeksiyon/RAMPS • Erken dönem sonuçları daha iyi • RDP'de açığa geçme oranı daha düşük							

LDP vs ODP							
Study	Year	Study type	PDAC patients	R0	LNR	OS (months)	Overall POPF* CR-POPF*
Kooby et al.	2010	Multi-institution (PM)	23 LDP vs 189 ODP	(74% vs 66%, $p=0.61$)	(14.0 vs 12.3, $p=0.41$)	(16 vs 16, $p=0.71$)	–
Shin et al.	2015	Single-institution (PM)	70 LDP vs 80 ODP	(75.7% vs 83.8%, $p=0.22$)	(12 vs 10, $p=0.13$)	(33.4 vs 29.1, $p=0.25$)	(18.6% vs 10.0%, $p=0.13$)
Zhang et al.	2015	Single-institution	17 LDP vs 34 ODP	(94.1% vs 85.3%, $p=0.650$)	(9 vs 8, $p=0.534$)	(14.0 vs 14.0, $p=0.802$)	(52.94% vs 47.05%, $p=0.48$)
Lee et al.	2015	Single-institution	19 LDP vs 249 ODP	(100% vs 88%, $p=0.21$)	(10.4 vs 15.4, $p=0.04$)	–	(6% vs 9%, $p=0.45$)
Xourafas et al.	2017	ACS-NSQIP	694 LDP vs 921 ODP	–	–	–	(18% vs 17%, $p=0.6484$)
LAPOP (Björnsson et al.)	2020	RCT	7 LDP vs 3 ODP	66.66% of LDP patients	15 in LDP patients	–	(31.03% vs 37.93%, $p=0.581$)
DIPLOMA (van Hilst et al.)	2019	Prospective (PM)	356 MIDP (240 LDP & 16 RDP) vs 856 ODP	(67% vs 58%, $p=0.019$)	(14 vs 22, $p<0.001$)	(28 vs 31, $p=0.774$)	(19% vs 20%, $p=0.921$)
LEOPARD-1 Trial (de Rooij et al.)	2019	RCT	13 MIDP vs 10 ODP	(53.84% vs 40%, $p=0.51$)	(11 vs 15, $p=0.71$)	–	(39% vs 23%, $p=0.07$)

*: Among PDAC and non-PDAC patients. -: data unavailable

RDP vs ODP							
Study	Year	Study type	PDAC patients	R0	LNR	OS (months)	Overall POPF* CR-POPF*
Lee et al.	2015	Single-institution	4 RDP vs 249 ODP	(100% vs 88%, $p=0.21$)	(12 vs 15.4, $p=0.04$)	–	(8% vs 12%, $p=0.45$) (5% vs 9%, $p=0.45$)
Nassour et al.	2020	NCDB	2,718 (332 RDP)	(17 vs 15, $p=0.002$)	(85% vs 81%, $p=0.293$)	(35.3 vs 24.9, $p=0.001$)	–
DIPLOMA (van Hilst et al.)	2019	Prospective (PM)	356 MIDP (240 LDP & 16 RDP) vs 856 ODP	(67% vs 58%, $p=0.019$)	(14 vs 22, $p<0.001$)	(28 vs 31, $p=0.774$)	(19% vs 20%, $p=0.921$)
LEOPARD-1 Trial (de Rooij et al.)	2019	RCT	13 MIDP vs 10 ODP	(53.84% vs 40%, $p=0.51$)	(11 vs 15, $p=0.71$)	–	(39% vs 23%, $p=0.07$)

*: Among PDAC and non-PDAC patients. -: data unavailable

RDP vs LDP							
Study	Year	Study type	PDAC patients	R0	LNR	OS (months)	Overall POPF* CR-POPF*
Lee et al.	2015	Single-institution	4 RDP vs 19 LDP	(100% vs 100%, $p=0.21$)	(12 vs 10.4, $p=0.04$)	–	(8% vs 8%, $p=0.45$) (5% vs 6%, $p=0.45$)
Zhou et al.	2016	Meta-analysis	32 RDP vs 40 LDP	OR=6.55, $p=0.10$	OR=1.94, $p=0.22$	–	OR=0.92, $p=0.71$

Total Pankreatektomi							
• Multisentrik (%6) PDAK • Yüksek Risk-POPF							

Outcomes After Minimally Invasive Versus Open Total Pancreatectomy
A Pan-European Propensity Score Matched Study

Lianne Scholten MD, PhD*¹ vs Sjors Klompmaker MD, PhD*²
 Jony Van Hilst MD, PhD, MSc*³ Maria M. Amecchiarelli MD, PhD†⁴
 Giampaolo Balzano MD‡⁵ Riccardo Grandi MD, PhD§⁶
 Jean-Michel Fabre MD, PhD||⁷ Massimo Falconi MD‡⁸ Giovanni Ferrari MD*⁹
 Mustafa Keren MD#¹⁰ Igor E. Kharikov MD, PhD**¹¹ Carlo Lombardo MD††¹²
 Alberto Manzoni MD‡‡¹³ Michele Mazzola MD††¹⁴ Nicolò Napoli MD††¹⁵
 Eduardo E. Rossu MD‡‡¹⁶ Pavel Tyutyunnik MD**¹⁷ Ulrich F. Wellner MD§§¹⁸
 David Fuks MD, PhD|||¹⁹ Fernando Burdus MD, PhD**²⁰ Tobias Keck MD§§²¹
 Mohammed Abu Hilal MD, PhD, FRCS, FACS‡‡††††²²
 Marc G. Besselink MD, PhD*²³ vs Ugo Boggi MD††²⁴ and

• 70/ 99 MITP
 • 70/ 262 OTP
 • Düşük major morbidite: %17 vs %31 (p<0.001)
 • Mortalite ve Hastanede kalış açısından fark yok.
 • Sağkalım farklı değil

Ann Surg ;277:2.; 313-20

www.cerrahionkoloji2024.org

Impact of Shifting from Laparoscopic to Robotic Surgery during 600 Minimally Invasive Pancreatic and Liver resections

Use of MIS-HPB resections increased from 30% to 45% (2014 - 2021)
 Overall conversion rate: 4.3%

163 pancreatoduodenectomy (111 robotic)
 128 distal pancreatectomy

198 laparoscopic liver resections
 111 robotic liver resections

Implementation of robotic surgery was associated with:

Pancreatoduodenectomy	Liver
Reduced operation time (450 min to 361 min; P<0.001)	Less overall complications (24.7% vs 10.8%; P=0.003)
Reduced blood loss (350 ml to 200 ml; P<0.001)	Shorter hospital stay (4 vs 3 days; P<0.001)
Higher lymph node retrieval (11 vs 14, P=0.016)	

Emmen, GÖRGEÇ et al. Surgical Endoscopy, September 2022

Sonuç

Pankreas Kanseriinde MI Cerrahi

Kısa Dönem Onkolojik Sonuçlar	Uzun Dönem Onkolojik Sonuçlar
Açık cerrahiye eşit veya üstün	Veriler sınırlı
	Onkolojik açıdan yetersiz değil
	Daha fazla çalışmaya ihtiyaç var

www.cerrahionkoloji2024.org

16th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association
 Dublin, Ireland | 10 - 12 June 2025

17. TÜRK HEPATO PANKREATO BİLİER CERRAHİ KONGRESİ

8. HEPATO PANKREATO BİLİER CERRAHİ HEMŞİRELİĞİ KONGRESİ

29 Ekim - 01 Kasım 2025
 Seginus Otel ve Kongre Merkezi, Antalya

TÜRK HEPATO PANKREATO BİLİER CERRAHİ DERNEĞİ